Extension of Time to File SOU

PYLARIFY

Progenics Pharmaceuticals, Inc.

Request for Extension of Time to File a Statement of Use

Under the Paperwork Reduction Act of 1995 no persons are required to respond to a collection of information unless it displays a valid OMB control number.
PTO Form 1581 (Rev 09/2005)
OMB No. 0651-0054 (Exp 12/31/2020)

Request for Extension of Time to File a Statement of Use
(15 U.S.C. Section 1051(d))


The table below presents the data as entered.

Input Field
Entered
SERIAL NUMBER 88647018
LAW OFFICE ASSIGNED LAW OFFICE 103
MARK SECTION
MARK PYLARIFY (see, http://uspto.report/TM/88647018/mark.png)
STANDARD CHARACTERS YES
USPTO-GENERATED IMAGE YES
LITERAL ELEMENT PYLARIFY
OWNER SECTION (current)
NAME Progenics Pharmaceuticals, Inc.
INTERNAL ADDRESS 47th Floor Suite J
MAILING ADDRESS One World Trade Center
CITY New York
STATE New York
ZIP/POSTAL CODE 10007
STATE/COUNTRY/REGION/JURISDICTION/U.S. TERRITORY United States
OWNER SECTION (proposed)
NAME Progenics Pharmaceuticals, Inc.
INTERNAL ADDRESS 47th Floor Suite J
MAILING ADDRESS One World Trade Center
CITY New York
STATE New York
ZIP/POSTAL CODE 10007
STATE/COUNTRY/REGION/JURISDICTION/U.S. TERRITORY United States
EMAIL XXXX
CORRESPONDENCE INFORMATION (current)
NAME PHI LAN M. TINSLEY
PRIMARY EMAIL ADDRESS FOR CORRESPONDENCE botrademarks@klgates.com
SECONDARY EMAIL ADDRESS(ES) (COURTESY COPIES) NOT PROVIDED
CORRESPONDENCE INFORMATION (proposed)
NAME Phi Lan M. Tinsley
PRIMARY EMAIL ADDRESS FOR CORRESPONDENCE botrademarks@klgates.com
SECONDARY EMAIL ADDRESS(ES) (COURTESY COPIES) kathleen.burch@klgates.com
DOCKET/REFERENCE NUMBER MIN.629.US
GOODS AND/OR SERVICES SECTION
INTERNATIONAL CLASS 005
CURRENT IDENTIFICATION Radiopharmaceutical imaging and detection agents for detection, diagnosing and monitoring cancer; pharmaceutical preparations for the detection, diagnosis, prevention, treatment and monitoring of cancer
GOODS OR SERVICES DELETED FROM THE APPLICATION OR INCLUDED IN A SEPARATELY FILED STATEMENT OF USE WITH A REQUEST TO DIVIDE prevention, treatment
GOODS OR SERVICES FOR WHICH APPLICANT HAS A CONTINUED BONA FIDE INTENTION, AND IS ENTITLED, TO USE Radiopharmaceutical imaging and detection agents for detection, diagnosing and monitoring cancer; pharmaceutical preparations for the detection, diagnosis and monitoring of cancer
INTERNATIONAL CLASS 042
CURRENT IDENTIFICATION Scientific research and development in the nature of research, development and preparation of pharmaceutical drugs and imaging agents for medical use; Providing temporary use of non-downloadable medical imaging software for the identification, quantification, diagnosis, prevention, treatment and monitoring of cancer
GOODS OR SERVICES KEEP ALL LISTED
INTERNATIONAL CLASS 044
CURRENT IDENTIFICATION Providing medical testing services and information in the field of cancer diagnosis, treatment and prevention; Web-based medical testing for identification, quantification, diagnostic or treatment purposes in the field of cancer; providing medical information in the field of cancer identification, diagnosis, treatment and prevention; medical imaging services
GOODS OR SERVICES KEEP ALL LISTED
REQUEST TO DIVIDE YES
EXTENSION SECTION
EXTENSION NUMBER 1
ALLOWANCE MAIL DATE 04/21/2020
STATEMENT OF USE YES
PAYMENT SECTION
NUMBER OF CLASSES 3
SUBTOTAL AMOUNT [EXTENSION FEE] 375
TOTAL AMOUNT 375
SIGNATURE SECTION
SIGNATURE /philan tinsley/
SIGNATORY'S NAME Phi Lan Tinsley
SIGNATORY'S POSITION Attorney of record, Massachusetts bar member
DATE SIGNED 06/17/2020
SIGNATORY'S PHONE NUMBER 617-261-3100
FILING INFORMATION
SUBMIT DATE Wed Jun 17 07:54:27 ET 2020
TEAS STAMP USPTO/ESU-XXX.XXX.XX.X-20
200617075427649463-886470
18-710719bc8b39d3bca63ec1
cf77f6c8522ed0d1563c15171
ccd6db5313782fe84-DA-5426
4495-20200617074926149074



Under the Paperwork Reduction Act of 1995 no persons are required to respond to a collection of information unless it displays a valid OMB control number.
PTO Form 1581 (Rev 09/2005)
OMB No. 0651-0054 (Exp 12/31/2020)


SOU Extension Request
(15 U.S.C. Section 1051(d))


To the Commissioner for Trademarks:

MARK: PYLARIFY (see, http://uspto.report/TM/88647018/mark.png)
SERIAL NUMBER: 88647018

OWNER AND/OR ENTITY INFORMATION
The owner proposes to amend the following:
Current: Progenics Pharmaceuticals, Inc., having an address of
      47th Floor Suite J
      One World Trade Center
      New York, New York 10007
      United States
Proposed: Progenics Pharmaceuticals, Inc., having an address of
      47th Floor Suite J
      One World Trade Center
      New York, New York 10007
      United States
      Phone:
      Fax:
      Email: XXXX

The owner requests a six-month extension of time to file the Statement of Use under 37 C.F.R. Section 2.89 in this application.    The Notice of Allowance mailing date was 04/21/2020.

For International Class 005:
Current identification: Radiopharmaceutical imaging and detection agents for detection, diagnosing and monitoring cancer; pharmaceutical preparations for the detection, diagnosis, prevention, treatment and monitoring of cancer

This filing does NOT cover the following goods/services listed in either the application or Notice of Allowance or as subsequently modified; these goods/services are either being permanently deleted or included in a separately filed Statement of Use with a Request to Divide: prevention, treatment

For a trademark/service mark: The applicant has a continued bona fide intention, and is entitled, to use the mark in commerce on or in connection with all of the goods/services listed in the Notice of Allowance or as subsequently modified for this specific class; for a collective/certification mark: the applicant has a continued bona fide intention, and is entitled, to exercise legitimate control over the use of the mark in commerce on or in connection with the goods/services/collective membership organization listed in the Notice of Allowance, or as subsequently modified for this specific class: Radiopharmaceutical imaging and detection agents for detection, diagnosing and monitoring cancer; pharmaceutical preparations for the detection, diagnosis and monitoring of cancer

For International Class 042:
Current identification: Scientific research and development in the nature of research, development and preparation of pharmaceutical drugs and imaging agents for medical use; Providing temporary use of non-downloadable medical imaging software for the identification, quantification, diagnosis, prevention, treatment and monitoring of cancer

For a trademark/service mark: The applicant has a continued bona fide intention, and is entitled, to use the mark in commerce on or in connection with all of the goods/services listed in the Notice of Allowance or as subsequently modified for this specific class; for a collective/certification mark: the applicant has a continued bona fide intention, and is entitled, to exercise legitimate control over the use of the mark in commerce on or in connection with the goods/services/collective membership organization listed in the Notice of Allowance, or as subsequently modified for this specific class.


For International Class 044:
Current identification: Providing medical testing services and information in the field of cancer diagnosis, treatment and prevention; Web-based medical testing for identification, quantification, diagnostic or treatment purposes in the field of cancer; providing medical information in the field of cancer identification, diagnosis, treatment and prevention; medical imaging services

For a trademark/service mark: The applicant has a continued bona fide intention, and is entitled, to use the mark in commerce on or in connection with all of the goods/services listed in the Notice of Allowance or as subsequently modified for this specific class; for a collective/certification mark: the applicant has a continued bona fide intention, and is entitled, to exercise legitimate control over the use of the mark in commerce on or in connection with the goods/services/collective membership organization listed in the Notice of Allowance, or as subsequently modified for this specific class.


The applicant has submitted a Request to Divide in paper or is filing a Request to Divide as part of the TEAS Allegation of Use form. This is the first extension request.

A Statement of Use has already been submitted or is being submitted along with the Extension request as evidence that applicant believes that it has made valid use of the mark in commerce.   If the USPTO finds the Statement of Use to be fatally defective, the applicant requests additional time to file an amended or substitute Statement of Use.

Correspondence Information (current):
      PHI LAN M. TINSLEY
      PRIMARY EMAIL FOR CORRESPONDENCE: botrademarks@klgates.com
      SECONDARY EMAIL ADDRESS(ES) (COURTESY COPIES): NOT PROVIDED

Correspondence Information (proposed):
      Phi Lan M. Tinsley
      PRIMARY EMAIL FOR CORRESPONDENCE: botrademarks@klgates.com
      SECONDARY EMAIL ADDRESS(ES) (COURTESY COPIES): kathleen.burch@klgates.com


Requirement for Email and Electronic Filing: I understand that a valid email address must be maintained by the owner/holder and the owner's/holder's attorney, if appointed, and that all official trademark correspondence must be submitted via the Trademark Electronic Application System (TEAS).





A fee payment in the amount of $375 will be submitted with the form, representing payment for 3 classes.


Declaration

STATEMENTS: The signatory believes that: the applicant has a continued bona fide intention, and is entitled, to use the mark in commerce on or in connection with all the goods/services under Section 1(b) in the notice of allowance or as subsequently modified, or, if applicable, the applicant has a continued bona fide intention, and is entitled, to exercise legitimate control over the use of the mark in commerce on or in connection with all the goods/services/collective membership organization under Section 1(b) in the notice of allowance or as subsequently modified; and that to the best of the signatory's knowledge and belief, no other persons, except, if applicable, members and concurrent users, have the right to use the mark in commerce, either in the identical form or in such near resemblance as to be likely, when used on or in connection with the goods/services/collective membership organization of such other persons, to cause confusion or mistake, or to deceive.

DECLARATION: The signatory being warned that willful false statements and the like are punishable by fine or imprisonment, or both, under 18 U.S.C. §1001, and that such willful false statements and the like may jeopardize the validity of the application or submission or any resulting registration, declares that all statements made of his/her own knowledge are true and that all statements made on information and belief are believed to be true.


Signature: /philan tinsley/      Date Signed: 06/17/2020
Signatory's Name: Phi Lan Tinsley
Signatory's Position: Attorney of record, Massachusetts bar member
Signatory's Phone: 617-261-3100

RAM Sale Number: 88647018
RAM Accounting Date: 06/17/2020

Serial Number: 88647018
Internet Transmission Date: Wed Jun 17 07:54:27 ET 2020
TEAS Stamp: USPTO/ESU-XXX.XXX.XX.X-20200617075427649
463-88647018-710719bc8b39d3bca63ec1cf77f
6c8522ed0d1563c15171ccd6db5313782fe84-DA
-54264495-20200617074926149074



Extension of Time to File SOU [image/jpeg]


uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.

© 2024 USPTO.report | Privacy Policy | Resources | RSS Feed of Trademarks | Trademark Filings Twitter Feed